- English (USA)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Bausch + Lomb Corp (BLCO)
Track today's live Bausch + Lomb (BLCO) share price, performance and key data on this page with our current NYSE:BLCO stock exchange information. Analyse interactive charts and historical data, check technical buy and sell signals in real time, and follow the Bausch + Lomb share price on the NYSE exchange. Use the dropdown to switch exchange for the BLCO share price, head to our technical summary section, which provides analysis on Bausch + Lomb share price buy/sell indicators using real-time data (or discuss the Bausch + Lomb (BLCO) stock price today with other investors in the Bausch + Lomb NYSE share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current NYSE:BLCO share price (ISIN: CA0717051076) to enhance your trading decisions with our free investment tools and resources.
What Is the Bausch + Lomb Corp Share Price Today?
The Bausch + Lomb share price today is 20.01.
What Is the Stock Symbol for Bausch + Lomb Corp
The stock symbol (or 'ticker') for Bausch + Lomb Corp is "BLCO."
What Stock Exchange Does Bausch + Lomb Corp Trade On?
Bausch + Lomb Corp is listed and trades on the NYSE stock exchange.
Is Bausch + Lomb Corp a Good Stock to Buy?
Determining whether Bausch + Lomb (or any stock) is a good buy requires comprehensive market analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and more than 1,200 other metrics.
Use the dropdown to select a relevant stock exchange for the current NYSE:BLCO share price (ISIN: CA0717051076) to enhance your trading decisions with our free investment tools and resources.
What Is the Bausch + Lomb Corp Share Price Today?
The Bausch + Lomb share price today is 20.01.
What Is the Stock Symbol for Bausch + Lomb Corp
The stock symbol (or 'ticker') for Bausch + Lomb Corp is "BLCO."
What Stock Exchange Does Bausch + Lomb Corp Trade On?
Bausch + Lomb Corp is listed and trades on the NYSE stock exchange.
Is Bausch + Lomb Corp a Good Stock to Buy?
Determining whether Bausch + Lomb (or any stock) is a good buy requires comprehensive market analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and more than 1,200 other metrics.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
19.68
20.22
52 wk Range
14.44
21.36
BLCO is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
19.6820.22
52 wk Range
14.4421.36
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
BLCO Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Price Target
21.71
Upside
+8.52%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
9 analysts have revised their earnings upwards for the upcoming period
Bausch + Lomb receives Investment Bank Analyst Rating Update- Investing.com
Pro
Bausch + Lomb receives Investment Bank Analyst Rating Update- Investing.com
Pro- Bausch + Lomb receives Investment Bank Analyst Rating Update
- Investing.com
Pro 
Form 144 Bausch & Lomb Corp For: 30 October- Investing.com
- Bausch + Lomb receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Form 144 Bausch & Lomb Corp For: 30 October
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Technical Indicators
Buy
Moving Averages
Buy
Analyst Ratings
6 Buy
8 Hold
1 Sell
Ratings:
15 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 21.71
(+8.52% Upside)
Bausch + Lomb Corp SWOT Analysis
Ophthalmology Leade | Bausch + Lomb, a $5.01B market cap company, dominates ophthalmology with diverse eye health products, facing spin-off uncertainties amid strong growth |
Financial Resilience | Despite mixed performance, B+L shows resilience with 11% Q4 growth and 59.68% gross profit margin. Analysts project EPS of $0.50 for FY2025 |
Market Dynamics | Explore B+L's strategic positioning in the competitive ophthalmology market, with focus on innovative Dry Eye Disease treatments and new product launches |
Future Prospects | Delve into B+L's growth strategy, aiming for 5.5-7.5% expansion in 2025. Analyst targets range from $12 to $22, reflecting varied market outlooks |
Bausch + Lomb Corp Earnings Call Summary for Q3/2026
- Bausch + Lomb Q3 adjusted EPS of $0.34 beat estimates by 61.9%; revenue rose 8% constant-currency to $1.38B, slightly topping forecasts.
- Adjusted EBITDA surged 34% to $325M with margin expanding 460bps to 23.6%; free cash flow hit $178M, strongest since 2022 IPO.
- Company raised 2026 guidance for third time: revenue $5.45B-$5.55B, EBITDA $1.09B-$1.14B, gross margin 62.5%-63.0%.
- Net leverage improved to 4.1x from 5.7x year-ago, moving toward 3.5x target; growth led by dry eye drugs, premium IOLs, contact lenses.
- Pipeline updates include next-gen LUMIFY launch H1 2027, Project Ilios FDA approval targeted by year-end 2026, dry AMD study early 2027.
Last Updated: 28/10/2026, 13:08
Read Full TranscriptEarnings
Latest Release
28/10/2026
EPS / Forecast
0.34 / 0.21
Revenue / Forecast
1.38B / 1.37B
Compare BLCO to Peers and Sector
Metrics to compare | BLCO | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipBLCOPeersSector | |
|---|---|---|---|---|
P/E Ratio | −64.4x | −0.7x | −0.2x | |
PEG Ratio | −1.01 | −0.58 | 0.00 | |
Price/Book | 1.1x | 1.7x | 2.6x | |
Price / LTM Sales | 1.3x | 1.9x | 2.8x | |
Upside (Analyst Target) | 8.5% | 11.3% | 65.5% | |
Fair Value Upside | Unlock | 15.6% | 8.9% | Unlock |
Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lenses that are indicated for therapeutic use and provide optical correction during healing. It also offers contact lens care products, eye vitamins, mineral supplements, and over-the-counter eye drops that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. The Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation operates as a subsidiary of Bausch Health Companies Inc.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Bausch + Lomb (NYSE: BLCO) Share Price Today?
The Bausch + Lomb stock price today is 20.01 USD.
What Stock Exchange Does Bausch + Lomb (BLCO) Trade On?
Bausch + Lomb is listed and trades on the New York Stock Exchange.
What Is the Ticker (Stock Symbol) for Bausch + Lomb?
The stock symbol (also called a 'ticker') for Bausch + Lomb is "BLCO."
What Is the Current Bausch + Lomb Market Capitalisation?
As of today, Bausch + Lomb (NYSE: BLCO) market cap is 7.15B USD.
What Is Bausch + Lomb's (BLCO) Earnings Per Share (TTM)?
The Bausch + Lomb EPS is currently -0.31 (Trailing Twelve Months).
When Is the Next Bausch + Lomb Earnings Date?
Bausch + Lomb's next earnings report will be released on 24/02/2027.
Is BLCO a Buy or Sell From a Technical Analyst Perspective?
Based on today's Bausch + Lomb moving averages and other technical indicators, the daily buy/sell signal for BLCO stock is Strong Buy.
How Many Times Has Bausch + Lomb Stock Split?
Bausch + Lomb has split 0 times. (See the BLCO stock split history page for full effective split date and price information.)
How Many Employees Does Bausch + Lomb Have?
Bausch + Lomb has 13000 employees, based on their latest Companies House report.
What is the current trading status of Bausch + Lomb (NYSE: BLCO)?
As of 03/11/2026, Bausch + Lomb (BLCO) is trading at a share price of 20.01 USD, with a previous close of 20.01 USD. The stock has fluctuated within a day range of 19.68 USD to 20.22 USD, while its 52-week range spans from 14.44 USD to 21.36 USD.
What Is Bausch + Lomb (BLCO) Price Target According to Analysts?
The average 12-month price target for Bausch + Lomb is 21.71 USD, with a high estimate of 26 USD and a low estimate of 18 USD. 6 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +8.52% Upside potential.
What Is the BLCO After Hours Price?
BLCO's last after hours stock price is 20.12 USD, the stock has decreased by 0.11, or 0.55%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.